Cells, mediators and Toll-like receptors in COPD

Chronic obstructive pulmonary disease (COPD) is a global health problem. Being a progressive disease characterized by inflammation, it deteriorates pulmonary functioning. Research has focused on airway inflammation, oxidative stress, and remodelling of the airways. Macrophages, neutrophils and T cel...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of pharmacology 2008-05, Vol.585 (2-3), p.346-353
Hauptverfasser: Sarir, Hadi, Henricks, Paul A.J., van Houwelingen, Anneke H., Nijkamp, Frans P., Folkerts, Gert
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 353
container_issue 2-3
container_start_page 346
container_title European journal of pharmacology
container_volume 585
creator Sarir, Hadi
Henricks, Paul A.J.
van Houwelingen, Anneke H.
Nijkamp, Frans P.
Folkerts, Gert
description Chronic obstructive pulmonary disease (COPD) is a global health problem. Being a progressive disease characterized by inflammation, it deteriorates pulmonary functioning. Research has focused on airway inflammation, oxidative stress, and remodelling of the airways. Macrophages, neutrophils and T cells are thought to be important key players. A number of new research topics received special attention in the last years. The combined use of inhaled corticosteroids and long-acting β2-adrenoceptor agonists produces better control of symptoms and lung function than that of the use of either compound alone. Furthermore, collagen breakdown products might be involved in the recruitment and activation of inflammatory cells by which the process of airway remodelling becomes self-sustaining. Also, TLR (Toll-like receptor)-based signalling pathways seem to be involved in the pathogenesis of COPD. These new findings may lead to new therapeutic strategies to stop the process of inflammation and self-destruction in the airways of COPD patients.
doi_str_mv 10.1016/j.ejphar.2008.03.009
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69135958</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0014299908002902</els_id><sourcerecordid>69135958</sourcerecordid><originalsourceid>FETCH-LOGICAL-c390t-4a0405bc3c470235893a2ccbf3b34a6cd724c6d3b37c7078b56da99ce4cf19813</originalsourceid><addsrcrecordid>eNp9kE1LxDAQhoMo7vrxD0R60ZOtkyb9yEWQ-gkL62E9h3SaYmq3XZOu4L83a4vePA0zPO8w8xByRiGiQNPrJtLN5k3ZKAbII2ARgNgjc5pnIoSMxvtkDkB5GAshZuTIuQYAEhEnh2RGc05B0HROoNBt666Cta6MGnrrAtVVwapv27A17zqwGvXmZ266oFi-3J2Qg1q1Tp9O9Zi8PtyviqdwsXx8Lm4XITIBQ8gVcEhKZMgziFmSC6ZixLJmJeMqxSqLOaaV7zLMIMvLJK2UEKg51lTklB2Ty3HvxvYfW-0GuTYO_bGq0_3WyVRQlogk9yAfQbS9c1bXcmPNWtkvSUHuTMlGjqbkzpQEJr0pHzuf9m9L__xfaFLjgYsJUA5VW1vVoXG_XAyMAxWJ525GTnsbn0Zb6dDoDr1QL2-QVW_-v-QbByeGcg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69135958</pqid></control><display><type>article</type><title>Cells, mediators and Toll-like receptors in COPD</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Sarir, Hadi ; Henricks, Paul A.J. ; van Houwelingen, Anneke H. ; Nijkamp, Frans P. ; Folkerts, Gert</creator><creatorcontrib>Sarir, Hadi ; Henricks, Paul A.J. ; van Houwelingen, Anneke H. ; Nijkamp, Frans P. ; Folkerts, Gert</creatorcontrib><description>Chronic obstructive pulmonary disease (COPD) is a global health problem. Being a progressive disease characterized by inflammation, it deteriorates pulmonary functioning. Research has focused on airway inflammation, oxidative stress, and remodelling of the airways. Macrophages, neutrophils and T cells are thought to be important key players. A number of new research topics received special attention in the last years. The combined use of inhaled corticosteroids and long-acting β2-adrenoceptor agonists produces better control of symptoms and lung function than that of the use of either compound alone. Furthermore, collagen breakdown products might be involved in the recruitment and activation of inflammatory cells by which the process of airway remodelling becomes self-sustaining. Also, TLR (Toll-like receptor)-based signalling pathways seem to be involved in the pathogenesis of COPD. These new findings may lead to new therapeutic strategies to stop the process of inflammation and self-destruction in the airways of COPD patients.</description><identifier>ISSN: 0014-2999</identifier><identifier>EISSN: 1879-0712</identifier><identifier>DOI: 10.1016/j.ejphar.2008.03.009</identifier><identifier>PMID: 18410916</identifier><identifier>CODEN: EJPHAZ</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>Adrenal Cortex Hormones - therapeutic use ; Adrenergic beta-Agonists - therapeutic use ; Animals ; Biological and medical sciences ; Chemokine ; Chemokines - physiology ; Chronic obstructive pulmonary disease, asthma ; COPD ; Corticosteroid ; Cytokines - physiology ; Epithelial Cells - physiology ; Humans ; Inflammation Mediators - physiology ; Leukocytes - physiology ; Medical sciences ; PGP ; Pharmacology. Drug treatments ; Pneumology ; Pulmonary Disease, Chronic Obstructive - drug therapy ; Pulmonary Disease, Chronic Obstructive - etiology ; Pulmonary Disease, Chronic Obstructive - pathology ; Pulmonary Disease, Chronic Obstructive - physiopathology ; Toll-like receptor ; Toll-Like Receptors - drug effects ; Toll-Like Receptors - physiology ; β2-adrenoceptor agonist</subject><ispartof>European journal of pharmacology, 2008-05, Vol.585 (2-3), p.346-353</ispartof><rights>2008 Elsevier B.V.</rights><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c390t-4a0405bc3c470235893a2ccbf3b34a6cd724c6d3b37c7078b56da99ce4cf19813</citedby><cites>FETCH-LOGICAL-c390t-4a0405bc3c470235893a2ccbf3b34a6cd724c6d3b37c7078b56da99ce4cf19813</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ejphar.2008.03.009$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=20340195$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18410916$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sarir, Hadi</creatorcontrib><creatorcontrib>Henricks, Paul A.J.</creatorcontrib><creatorcontrib>van Houwelingen, Anneke H.</creatorcontrib><creatorcontrib>Nijkamp, Frans P.</creatorcontrib><creatorcontrib>Folkerts, Gert</creatorcontrib><title>Cells, mediators and Toll-like receptors in COPD</title><title>European journal of pharmacology</title><addtitle>Eur J Pharmacol</addtitle><description>Chronic obstructive pulmonary disease (COPD) is a global health problem. Being a progressive disease characterized by inflammation, it deteriorates pulmonary functioning. Research has focused on airway inflammation, oxidative stress, and remodelling of the airways. Macrophages, neutrophils and T cells are thought to be important key players. A number of new research topics received special attention in the last years. The combined use of inhaled corticosteroids and long-acting β2-adrenoceptor agonists produces better control of symptoms and lung function than that of the use of either compound alone. Furthermore, collagen breakdown products might be involved in the recruitment and activation of inflammatory cells by which the process of airway remodelling becomes self-sustaining. Also, TLR (Toll-like receptor)-based signalling pathways seem to be involved in the pathogenesis of COPD. These new findings may lead to new therapeutic strategies to stop the process of inflammation and self-destruction in the airways of COPD patients.</description><subject>Adrenal Cortex Hormones - therapeutic use</subject><subject>Adrenergic beta-Agonists - therapeutic use</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Chemokine</subject><subject>Chemokines - physiology</subject><subject>Chronic obstructive pulmonary disease, asthma</subject><subject>COPD</subject><subject>Corticosteroid</subject><subject>Cytokines - physiology</subject><subject>Epithelial Cells - physiology</subject><subject>Humans</subject><subject>Inflammation Mediators - physiology</subject><subject>Leukocytes - physiology</subject><subject>Medical sciences</subject><subject>PGP</subject><subject>Pharmacology. Drug treatments</subject><subject>Pneumology</subject><subject>Pulmonary Disease, Chronic Obstructive - drug therapy</subject><subject>Pulmonary Disease, Chronic Obstructive - etiology</subject><subject>Pulmonary Disease, Chronic Obstructive - pathology</subject><subject>Pulmonary Disease, Chronic Obstructive - physiopathology</subject><subject>Toll-like receptor</subject><subject>Toll-Like Receptors - drug effects</subject><subject>Toll-Like Receptors - physiology</subject><subject>β2-adrenoceptor agonist</subject><issn>0014-2999</issn><issn>1879-0712</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1LxDAQhoMo7vrxD0R60ZOtkyb9yEWQ-gkL62E9h3SaYmq3XZOu4L83a4vePA0zPO8w8xByRiGiQNPrJtLN5k3ZKAbII2ARgNgjc5pnIoSMxvtkDkB5GAshZuTIuQYAEhEnh2RGc05B0HROoNBt666Cta6MGnrrAtVVwapv27A17zqwGvXmZ266oFi-3J2Qg1q1Tp9O9Zi8PtyviqdwsXx8Lm4XITIBQ8gVcEhKZMgziFmSC6ZixLJmJeMqxSqLOaaV7zLMIMvLJK2UEKg51lTklB2Ty3HvxvYfW-0GuTYO_bGq0_3WyVRQlogk9yAfQbS9c1bXcmPNWtkvSUHuTMlGjqbkzpQEJr0pHzuf9m9L__xfaFLjgYsJUA5VW1vVoXG_XAyMAxWJ525GTnsbn0Zb6dDoDr1QL2-QVW_-v-QbByeGcg</recordid><startdate>20080513</startdate><enddate>20080513</enddate><creator>Sarir, Hadi</creator><creator>Henricks, Paul A.J.</creator><creator>van Houwelingen, Anneke H.</creator><creator>Nijkamp, Frans P.</creator><creator>Folkerts, Gert</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20080513</creationdate><title>Cells, mediators and Toll-like receptors in COPD</title><author>Sarir, Hadi ; Henricks, Paul A.J. ; van Houwelingen, Anneke H. ; Nijkamp, Frans P. ; Folkerts, Gert</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c390t-4a0405bc3c470235893a2ccbf3b34a6cd724c6d3b37c7078b56da99ce4cf19813</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adrenal Cortex Hormones - therapeutic use</topic><topic>Adrenergic beta-Agonists - therapeutic use</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Chemokine</topic><topic>Chemokines - physiology</topic><topic>Chronic obstructive pulmonary disease, asthma</topic><topic>COPD</topic><topic>Corticosteroid</topic><topic>Cytokines - physiology</topic><topic>Epithelial Cells - physiology</topic><topic>Humans</topic><topic>Inflammation Mediators - physiology</topic><topic>Leukocytes - physiology</topic><topic>Medical sciences</topic><topic>PGP</topic><topic>Pharmacology. Drug treatments</topic><topic>Pneumology</topic><topic>Pulmonary Disease, Chronic Obstructive - drug therapy</topic><topic>Pulmonary Disease, Chronic Obstructive - etiology</topic><topic>Pulmonary Disease, Chronic Obstructive - pathology</topic><topic>Pulmonary Disease, Chronic Obstructive - physiopathology</topic><topic>Toll-like receptor</topic><topic>Toll-Like Receptors - drug effects</topic><topic>Toll-Like Receptors - physiology</topic><topic>β2-adrenoceptor agonist</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sarir, Hadi</creatorcontrib><creatorcontrib>Henricks, Paul A.J.</creatorcontrib><creatorcontrib>van Houwelingen, Anneke H.</creatorcontrib><creatorcontrib>Nijkamp, Frans P.</creatorcontrib><creatorcontrib>Folkerts, Gert</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sarir, Hadi</au><au>Henricks, Paul A.J.</au><au>van Houwelingen, Anneke H.</au><au>Nijkamp, Frans P.</au><au>Folkerts, Gert</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cells, mediators and Toll-like receptors in COPD</atitle><jtitle>European journal of pharmacology</jtitle><addtitle>Eur J Pharmacol</addtitle><date>2008-05-13</date><risdate>2008</risdate><volume>585</volume><issue>2-3</issue><spage>346</spage><epage>353</epage><pages>346-353</pages><issn>0014-2999</issn><eissn>1879-0712</eissn><coden>EJPHAZ</coden><abstract>Chronic obstructive pulmonary disease (COPD) is a global health problem. Being a progressive disease characterized by inflammation, it deteriorates pulmonary functioning. Research has focused on airway inflammation, oxidative stress, and remodelling of the airways. Macrophages, neutrophils and T cells are thought to be important key players. A number of new research topics received special attention in the last years. The combined use of inhaled corticosteroids and long-acting β2-adrenoceptor agonists produces better control of symptoms and lung function than that of the use of either compound alone. Furthermore, collagen breakdown products might be involved in the recruitment and activation of inflammatory cells by which the process of airway remodelling becomes self-sustaining. Also, TLR (Toll-like receptor)-based signalling pathways seem to be involved in the pathogenesis of COPD. These new findings may lead to new therapeutic strategies to stop the process of inflammation and self-destruction in the airways of COPD patients.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>18410916</pmid><doi>10.1016/j.ejphar.2008.03.009</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0014-2999
ispartof European journal of pharmacology, 2008-05, Vol.585 (2-3), p.346-353
issn 0014-2999
1879-0712
language eng
recordid cdi_proquest_miscellaneous_69135958
source MEDLINE; Access via ScienceDirect (Elsevier)
subjects Adrenal Cortex Hormones - therapeutic use
Adrenergic beta-Agonists - therapeutic use
Animals
Biological and medical sciences
Chemokine
Chemokines - physiology
Chronic obstructive pulmonary disease, asthma
COPD
Corticosteroid
Cytokines - physiology
Epithelial Cells - physiology
Humans
Inflammation Mediators - physiology
Leukocytes - physiology
Medical sciences
PGP
Pharmacology. Drug treatments
Pneumology
Pulmonary Disease, Chronic Obstructive - drug therapy
Pulmonary Disease, Chronic Obstructive - etiology
Pulmonary Disease, Chronic Obstructive - pathology
Pulmonary Disease, Chronic Obstructive - physiopathology
Toll-like receptor
Toll-Like Receptors - drug effects
Toll-Like Receptors - physiology
β2-adrenoceptor agonist
title Cells, mediators and Toll-like receptors in COPD
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T07%3A49%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cells,%20mediators%20and%20Toll-like%20receptors%20in%20COPD&rft.jtitle=European%20journal%20of%20pharmacology&rft.au=Sarir,%20Hadi&rft.date=2008-05-13&rft.volume=585&rft.issue=2-3&rft.spage=346&rft.epage=353&rft.pages=346-353&rft.issn=0014-2999&rft.eissn=1879-0712&rft.coden=EJPHAZ&rft_id=info:doi/10.1016/j.ejphar.2008.03.009&rft_dat=%3Cproquest_cross%3E69135958%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69135958&rft_id=info:pmid/18410916&rft_els_id=S0014299908002902&rfr_iscdi=true